Terray Therapeutics CEO Jacob Berlin (L) and CFO/COO Eli Berlin
October 17, 2024 07:30 AM EDTUpdated 08:50 AM
Financing
AI

Ex­clu­sive: Ter­ray rais­es $120M for its AI ways of de­sign­ing mol­e­cules

Andrew Dunn

Senior Biopharma Correspondent

Ter­ray Ther­a­peu­tics has raised a $120 mil­lion Se­ries B round, aim­ing to get its first drug can­di­date in­to the clin­ic while ad­vanc­ing in its AI …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Sage shakes up se­nior man­age­ment, slash­es pipeline, sheds 33% of staff

No­var­tis pays $70M up­front to li­cense Chi­nese biotech’s an­ti­tu­mor drug

Sanofi in­vests in new ra­di­oli­gand part­ner Ora­no Med, buy­ing 16% stake for €300M

First clin­i­cal test of RNA edit­ing re­stores miss­ing pro­tein in ge­net­ic dis­ease, Wave says

FDA lead­ers kick off rare dis­ease hub to in­crease cross-cen­ter col­lab­o­ra­tion

sponsored

Join the Gen­Script Biotech Glob­al Fo­rum: Un­lock­ing In­no­va­tions in Cell and Gene Ther­a­pies

A service from the Financial Times